BI 1815368
Unknown / undisclosed
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
THULITE NCT06962839 · Macular Edema Registry: NCT06962839 | 2 | Occurrence (yes/no) of a gain of ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters compared with baseline in the study eye at Week 48 (at baseline, at week 48) 2028-03-01 | In progress: results expected 1 Mar 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Diabetic Macular Edema: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| BI 1815368: this drug | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Abzv (Enzeevu) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Boav (Eydenzelt) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Brolucizumab-Dbll | Approved | Antibody fragment | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| Faricimab | Approved | Multispecific antibody | Angiopoietin-2 / VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Lucentis) | Approved | Antibody fragment | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Eqrn (Cimerli) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| RC28-E | Phase 3 | Protein / enzyme therapeutic | VEGF-A / FGF-2 (dual blockade) | Partial signal | NCT05885503: Primary endpoint, mean BCVA change at week 52: non-inferior to aflibercept 2.0 mg (316 subjects) (2025-09-30). | |
| Tabirafusp Tedromer | Phase 3 | Multispecific antibody | VEGF + IL-6 | not yet graded | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| MK-3000 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6209 | —(overall) | Antibody fragment | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6697 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6913 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow BI 1815368 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.